Gilead Sciences Stock Rallies Following Improving Survival of Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences Good News for Breast Cancer
Gilead Sciences' (GILD) product Trodelvy® has significantly improved the Overall Survival (OS) in Pre-Treated HR+/HER2- metastatic breast cancer patients in the TROPiCS-02 study.

Today, Gilead Sciences' (This content is for paid subscribers.

Please click here to subscribe or here to log in.